CAR T-Cell Therapy for Acute Lymphoblastic Leukemia Market to Grow Significantly at a CAGR of 6.8% During the Forecast Period (2026-2036), Driven by Emerging Therapies and Expanding Pipeline | DelveInsight

Lasme-celPositive

AI Analysis

Summary

Market analysis report projects CAR T-cell therapy for acute lymphoblastic leukemia will grow at a CAGR of 6.8% through 2036, driven by emerging therapies including Lasme-cel (UCART22) and expanded R&D efforts.

Importance:2/10

Sentiment:

0.30

CAR T-cell therapyAcute Lymphoblastic LeukemiaMarket analysisPipeline expansion

Read the original article

Published by PR Newswire Biotech on August 12, 2026 2:31 PM

Read Original